Browse > Article

Comparison of Effect Between Thrombolysis and Anticoagulation in Major Pulmonary Thromboembolism  

Han, Song Yi (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Song, Jae Kwan (Divisions of Cardiology, University of Ulsan College of Medicine, Asan Medical Center)
Lee, Sang Do (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Lim, Chae-Man (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Koh, Younsuck (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Park, Chan Sun (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Oh, Yeon Mok (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Shim, Tae Sun (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Woo Sung (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Dong Soon (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Won Dong (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Hong, Sang-Bum (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
Publication Information
Tuberculosis and Respiratory Diseases / v.59, no.5, 2005 , pp. 487-496 More about this Journal
Abstract
Background : 'Major pulmonary thromboembolism' is defined as right ventricular (RV) dysfunction, with or without shock, accompanied by significant morbidity and mortality. In this study, those with major pulmonary thromboembolism were divided into the shock and RV dysfunction only groups, and then investigated the mortality and complications in thrombolysis or anticoagulation, respectively. Methods : In a retrospective study, between January 1995 and December 2004, 60 eligible patients with a major pulmonary thromboembolism, admitted in Asan Medical Center, were included. Results : A total of 57 patients were treated with medical therapy. Thrombolysis was performed in 13 patients (23%) and anticoagulation in 44 (77%). There were no differences in the APACHEII and SOFA scores between the two groups. 6 (46%) and 11 (25%) patients died in the thrombolysis and anticoagulation groups, respectively (p=0.176). In the 19 patients (33%) showing shock, thrombolysis was performed in 9 (47%) and anticoagulation in 10 (53%). 4 (44%) of the 9 patients treated with thrombolytic agents and 3 (30%) of the 10 treated with anticoagulants died (p=0.650). In the 38 patients (67%) showing RV dysfunction only, thrombolysis was performed in 4 (11%) and anticoagulation in 34 (89%). 2 (50%) of the 4 patients treated with thrombolytics and 8 (24%) of the 34 treated with anticoagulants died (p=0.279). Three patients (23%) who underwent thrombolysis had a major bleeding episode, compared with 2 (5%) who were treated with anticoagulants (p=0.072). Conclusion: The results of our study showed that thrombolysis did not lower mortality and tended to increase major bleeding compared with anticoagulation in both the shock and RV dysfunction only groups. Further evaluation of the efficacy and safety of thrombolytic therapy for major thromboembolism appears warranted in Korea.
Keywords
Major pulmonary thromboembolism; Thrombolysis; Anticoagulation RV dysfunction; Shock;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8   DOI   ScienceOn
2 Goldhaber SZ, Visani L, de Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-9   DOI   PUBMED   ScienceOn
3 Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346-9   DOI
4 Harmel E, Pacouret G, Vincentelli D, Forissier JF, Peycher P, Pottier JM, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001;120:120-5   DOI   ScienceOn
5 Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999;115:1695-707   DOI   ScienceOn
6 Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a twohour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998;31:1057-63   DOI   ScienceOn
7 Chan LC, Bourke C, Lam CK, Liu HW, Brookes S, Pasi J, et al. Lack of activation protein C resistance in healthy Hong Kong Chinese blood donors: correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost 1996;75:522-3
8 Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110:744-9   DOI   ScienceOn
9 Konstantinides S, Geibel A, Kasper W. Predictors of in-hospital mortality in patients with acute massive pulmonary embolism: results of the Management and Prognosis of Pulmonary Embolism Registry. Circulation 1996;94(Suppl I):I572
10 Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camati A, Santoro G, et al. Short-term clinical outcome of patients with pulmonary embolism, normal blood pressure and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817-22   DOI   ScienceOn
11 Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Gent M, et al. A randomized trial of single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9   DOI   ScienceOn
12 Urokinase pulmonary embolism trial: phase 1 results: a cooperative study. JAMA 1970;214:2163-72   DOI   PUBMED   ScienceOn
13 Takamiya O, Ishida F, Kodaira H, Kitano K. APCresistance and Mnl I genotype(Gln 506. coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996
14 Bak SM, Lee SH, Sin C, Cho JY, Shim JJ, In KH, et al. Clinical study of pulmonary thromboembolism. Tuberc Respir Dis 2001;50:106-16   DOI
15 The urokinase pulmonary embolism trial: a national cooperative study. Circulation 1973;47(Suppl 2):II1-108   DOI   ScienceOn
16 Kim TW, Kim WK, Zang DY, Lee JH, Kim SB, Kim SW, et al. The prevalence of Leiden(1961$G{\rightarrow}A$. mutation in the factor V gene in Korean patients suspected to have thrombosis. Korean J Thromb Hemost 1997;4: 27-31
17 Yoon TR, Rowe SM, Song EK, Seon JK. Deep vein thrombosis after total hip replacement: incidence and correlation between DVT and its risk factors. J Korean Othrop Assoc 2000:35;205-10
18 Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JF. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-80   DOI   ScienceOn
19 Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of multicenter registry. J Am Coll Cardiol 1997;30:1165-71   DOI   ScienceOn
20 Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. J Am Coll Cardiol 1992;20:520-6   DOI
21 The PIOPED investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990;97:528-33   DOI   PUBMED   ScienceOn
22 Chan W, Chan T. Thrombolysis for acute pulmonary embolism in Chinese patients. QJM 2000;93:125-7   DOI   ScienceOn
23 Hall RJ, Sutton GC, Kerr IH. Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J 1977;39:1128-34   DOI   ScienceOn
24 Geerts WH, Pineo GF, Heit JA, Bergqvit D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126: 338S-400S   DOI   ScienceOn
25 Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:2537-41   DOI   ScienceOn
26 Scientific Committee for National Survey of Acute Pulmonary Thromboembolism, Korea Academy of Tuberculosis and Respiratory Disease. The National survey of acute pulmonary thromboembolism in Korea. Tuberc Respir Dis 2003;54:5-14   DOI
27 Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-50   DOI   ScienceOn